1. Neither evidence from the PROactive study nor the KPNC supports pioglitazone as a tumour promoter. Issue 4 (April 2015) Authors: Ryder, R. E. J. Journal: Diabetic medicine Issue: Volume 32:Issue 4(2015:Apr.) Page Start: 438 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Pioglitazone has a dubious bladder cancer risk but an undoubted cardiovascular benefit. Issue 3 (3rd December 2014) Authors: Ryder, R. E. J. Journal: Diabetic medicine Issue: Volume 32:Issue 3(2015:Mar.) Page Start: 305 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Pioglitazone: reports of its death are greatly exaggerated1 – it is alive and ready to resume saving lives. Issue 4 (April 2015) Authors: Ryder, R. E. J. Journal: Diabetic medicine Issue: Volume 32:Issue 4(2015:Apr.) Page Start: e9 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Revitalization of pioglitazone: the optimum agent to be combined with a sodium‐glucose co‐transporter‐2 inhibitor. Issue 5 (6th April 2016) Authors: DeFronzo, R. A.; Chilton, R.; Norton, L.; Clarke, G.; Ryder, R. E. J.; Abdul‐Ghani, M. Journal: Diabetes, obesity & metabolism Issue: Volume 18:Issue 5(2016) Page Start: 454 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. The association between postprandial urinary C‐peptide creatinine ratio and the treatment response to liraglutide: a multi‐centre observational study. Issue 4 (6th December 2013) Authors: Thong, K. Y.; McDonald, T. J.; Hattersley, A. T.; Blann, A. D.; Ramtoola, S.; Duncan, C.; Carr, S.; Adamson, K.; Nayak, A. U.; Khurana, R.; Hunter, S. J.; Ali, A.; Au, S.; Ryder, R. E. J. Journal: Diabetic medicine Issue: Volume 31:Issue 4(2014:Apr.) Page Start: 403 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. The Association of British Clinical Diabetologists nationwide exenatide and liraglutide audits suggest a low incidence of acute pancreatitis. Response to Robson. Incretins and pancreatitis—what happens next? A personal viewpoint. Issue 12 (December 2013) Authors: Ryder, R. E. J.; Sen Gupta, P.; Thong, K. Y. Journal: Diabetic medicine Issue: Volume 30:Issue 12(2013:Dec.) Page Start: 1510 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. The potential risks of pancreatitis and pancreatic cancer with GLP‐1‐based therapies are far outweighed by the proven and potential (cardiovascular) benefits. Issue 10 (16th September 2013) Authors: Ryder, R. E. J. Journal: Diabetic medicine Issue: Volume 30:Issue 10(2013:Oct.) Page Start: 1148 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗